Puma Biotechnology (NASDAQ:PBYI – Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.06, FiscalAI reports. Puma Biotechnology had a net margin of 11.50% and a return on equity of 20.76%. The business had revenue of $55.10 million for the quarter, compared to the consensus estimate of $57.50 million.
Here are the key takeaways from Puma Biotechnology’s conference call:
- Q3 revenue was $55.1 million, with net product revenue of $54.1 million, up from $53.6 million in Q2. However, U.S. NERLYNX net sales fell to $50.6 million from $53.6 million, while $3.6 million of product-supply revenue came from international partners.
- NERLYNX demand was mixed: U.S. demand rose 5% year over year but fell 3% quarter over quarter, while new patient starts declined 9% year over year and 13% sequentially. The company also lowered its 2026 product-revenue outlook slightly and cut its royalty forecast to $18–$19 million from $20–$23 million, citing a China royalty-rate reduction after generic market share crossed a threshold.
- Puma raised its full-year 2026 net-income outlook to $20–$22 million from $17–$20 million and expects $10–$12 million in Q4 net income. It ended Q3 with $108.5 million in cash, cash equivalents, and marketable securities and is now debt-free.
- Puma said preliminary ALISCA-Breast1 data supports considering a Phase III alisertib trial; updated interim results are expected at the San Antonio Breast Cancer Symposium in December, with discussions with regulators planned for the first half of 2027. The company also expects additional ALISCA-Lung1 interim data and initial ALISCA-Lung2 data in 2027, though these remain investigational programs.
Puma Biotechnology Price Performance
Shares of PBYI stock traded down $1.52 on Friday, reaching $8.25. 1,279,729 shares of the stock were exchanged, compared to its average volume of 359,117. The stock has a market cap of $425.87 million, a PE ratio of 17.94 and a beta of 1.40. Puma Biotechnology has a one year low of $4.57 and a one year high of $11.50. The stock has a 50 day moving average price of $9.88 and a 200 day moving average price of $7.99.
Analysts Set New Price Targets
Several research firms have weighed in on PBYI. Wall Street Zen upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Weiss Ratings upgraded shares of Puma Biotechnology from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Finally, TD Cowen increased their price target on shares of Puma Biotechnology from $5.00 to $6.00 and gave the company a “hold” rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Puma Biotechnology currently has a consensus rating of “Moderate Buy” and an average price target of $6.00.
View Our Latest Research Report on PBYI
Insider Activity
In related news, Director Alessandra Cesano sold 62,150 shares of Puma Biotechnology stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $9.12, for a total value of $566,808.00. Following the completion of the sale, the director directly owned 56,700 shares in the company, valued at $517,104. This trade represents a 52.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Troy Wilson sold 5,000 shares of the business’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $9.10, for a total value of $45,500.00. Following the sale, the director directly owned 54,750 shares of the company’s stock, valued at $498,225. This represents a 8.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 22.20% of the stock is owned by company insiders.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company focused on developing and commercializing medicines for the treatment of cancer. The company’s lead product is NERLYNX (neratinib), an oral, irreversible tyrosine kinase inhibitor designed to target HER2 and other members of the epidermal growth factor receptor family.
NERLYNX is approved in the United States for the extended adjuvant treatment of adults with early-stage, HER2-positive breast cancer following adjuvant trastuzumab-based therapy.
Read More
- Five stocks we like better than Puma Biotechnology
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.PNG){kind=logo}